Patents Assigned to Umwelt (GmbH)
-
Publication number: 20240107988Abstract: Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.Type: ApplicationFiled: January 27, 2022Publication date: April 4, 2024Applicants: UNIVERSITAT AUTÒNOMA DE BARCELONA, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Maria Fátima BOSCH TUBERT, Verónica JIMENEZ CENZANO, Miquel GARCIA MARTINEZ, Estefanía CASANA LORENTE, Martin Matthias HRABE DE ANGELIS, Gerhard Kurt Herbert PRZEMECK, Anna-Lena AMEND
-
Patent number: 11923182Abstract: Devices and methods for mass spectroscopic analysis of particles are disclosed herein. An example device includes: a first irradiation unit configured to irradiate a particle with electromagnetic radiation to cause components of the particle to detach from the particle. The example device further includes a second irradiation unit configured to irradiate substantially simultaneously i) at least a part of the detached components, and optionally a residual core of the particle, with a first beam of electromagnetic radiation the first beam of electromagnetic radiation exhibiting a first intensity, and ii) at least a part of the residual core, of the particle with a second beam of electromagnetic radiation. The second beam of electromagnetic radiation exhibiting a second intensity, which is preferably larger than the first intensity. The example device further includes a mass spectrometer comprising an ion source region, a first detection channel, and optionally a second detection channel.Type: GrantFiled: April 8, 2019Date of Patent: March 5, 2024Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)Inventors: Ralf Zimmermann, Johannes Passig, Sven Ehlert
-
Patent number: 11857290Abstract: The invention relates to a device (1) for endoscopic optoacoustic imaging comprising an imaging unit (2) configured to be at least partially inserted into an object (5), said imaging unit (2) comprising an irradiation unit (6) configured to irradiate a region of interest (7) inside the object (5) with electromagnetic radiation and a detection unit (8) comprising at least one ultrasound transducer configured to detect ultrasound waves generated in the region of interest (7) in response to irradiating the region of interest (7) with the electromagnetic radiation and to generate according detection signals, wherein the at least one ultrasound transducer exhibits a field of view (8b) being at least partially located in the irradiated region of interest (7).Type: GrantFiled: August 14, 2018Date of Patent: January 2, 2024Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit und Umwelt (GmbH)Inventors: Vasilis Ntziachristos, George Sergiadis, Christian Zakian, Andreas Buehler
-
Publication number: 20230408399Abstract: An apparatus for photo-acoustic measurement of a measurement target in a fluid flow comprises:—an ellipsoidal measurement chamber (3) having a first focal point and a second focal point; —a duct (6, 7, 8) configured to guide a fluid flow through the measurement chamber (3) along a first axis (X) through the first focal point; —light source means for generating an excitation light beam of modulated intensity; —means configured to pass the excitation light beam through the measurement chamber (3) along a second axis (Y), which is different from the first axis (X), such that the excitation light beam crosses the fluid flow at the first focal point and that the crossing of the fluid flow and the excitation light beam defines an excitation volume (4) within which the fluid flow is excited by the excitation light beam to generate acoustic waves; and —detecting means (5) arranged at the second focal point and configured to detect said acoustic waves, wherein the detecting means has no direct contact with the fluid fType: ApplicationFiled: October 29, 2021Publication date: December 21, 2023Applicants: ARISTOTLE UNIVERSITY OF THESSALONIKI - E.L.K.E., HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)Inventors: Leonidas Ntziachristos, Nikolaos Kousias, Vasilis Ntziachristos, Anastasios Kontses, Antonios Stylogiannis
-
Publication number: 20230330111Abstract: The present invention relates to a kit-of-parts comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug and its use in medicine. The invention further relates to a pharmaceutical composition comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug for use in medicine. Moreover, the invention is directed to the kit-of-parts and the pharmaceutical composition for use in the treatment of cancer, in particular glioma, pancreatic cancer, small cell lung cancer, metastatic prostate cancer, liver cancer and triple-negative breast cancer.Type: ApplicationFiled: August 27, 2021Publication date: October 19, 2023Applicant: HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Götz HARTLEBEN, Mauricio BERRIEL DIAZ, Stephan HERZIG, Tobias SCHAFMEIER
-
Patent number: 11733236Abstract: The present invention relates to the use of the biomarker Flattop (Fltp) for distinguishing mature ? cells from immature progenitor ? cells. The present invention further relates to a method for distinguishing a mature ? cell from an immature progenitor ? cell, the method comprising: determining the presence or absence of the biomarker Flattop (Fltp) in a ? cell; wherein the presence of Fltp in the cell indicates that the cell is a mature ? cell and wherein the absence of Fltp in the cell indicates that the cell is an immature progenitor ? cell. Furthermore, the present invention relates to a method of identifying a compound suitable for differentiating immature progenitor ? cells into mature ? cells as well as to a method of identifying a compound suitable for preventing the de-differentiating of mature ? cells. The present invention additionally relates to a method of differentiating immature progenitor ? cells into mature ? cells as well as to a method of preventing de-differentiating of mature ? cells.Type: GrantFiled: November 14, 2019Date of Patent: August 22, 2023Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH)Inventors: Heiko Lickert, Adriana Migliorini, Moritz Gegg, Erik Bader
-
Publication number: 20230250416Abstract: The present invention relates to a method for detecting a nucleic acid construct or part thereof and/or for detecting the expression product of the nucleic acid construct or part thereof, wherein the method comprises inserting a nucleic acid construct or part thereof into an intron or a synthetic intron, wherein the nucleic acid construct comprises certain defined structures according to the present invention. The present invention also relates to the various uses of the method described herein, to the nucleic acid construct, a vector comprising said nucleic acid construct, a cell comprising said nucleic acid construct and/or said vector, and a respective kit.Type: ApplicationFiled: July 6, 2021Publication date: August 10, 2023Applicants: HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHENInventors: Gil Gregor WESTMEYER, Dong-Jiunn Jeffery TRUONG
-
Publication number: 20230203440Abstract: The present invention relates to methods of producing axial stem cells (AxSCs) as well to axial stem cells (AxSCs) produced by such methods and uses thereof. The present invention further relates to axial stem cells (AxSCs), wherein said axial stem cells are not pluripotent cells, but are, for example, region-specific multipotent stem cells capable of indefinitely renewing themselves.Type: ApplicationFiled: May 25, 2021Publication date: June 29, 2023Applicant: HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)Inventors: Micha DRUKKER, Dmitry SHAPOSHNIKOV, Aicha Haji ALI, Dolunay KELLE-OZDEMIR, Ejona RUSHA
-
Patent number: 11602560Abstract: The present invention provides herpesviruses, such as EBV, which lack at least one viral miRNA. Such herpesviruses lacking at least one viral miRNA are advantageously not capable of packaging their genome into the capsid, thereby producing HVLPs, which are substantially free of their herpesvirus genome or the nucleic acid molecule encoding the proteinaceous part of the HVLP and viral miRNA. Such HVLPs may be used as vaccine.Type: GrantFiled: February 28, 2017Date of Patent: March 14, 2023Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Wolfgang Hammerschmidt, Reinhard Zeidler, Dagmar Pich
-
Patent number: 11596312Abstract: The invention relates to a device (1) and an according method for optoacoustic imaging of an object. The device (1) comprising an irradiation unit for irradiating a region of interest (3) of the object with electromagnetic radiation (6), in particular light, and a detection unit (9) for detecting acoustic, in particular ultrasonic, waves generated in the region of interest (3) of the object upon irradiation with the electromagnetic radiation (6), wherein the detection unit (9) is configured to detect the acoustic waves at one or more point-like detection locations, which are located outside of the region of interest (3) of the object. The point-like detection locations can be given by, e.g., focus points (19) of acoustic detection elements (23), point-like detection elements or point-like or pinhole apertures. The invention allows for improved and reliable optoacoustic imaging, in particular in view of dermatology applications.Type: GrantFiled: May 12, 2015Date of Patent: March 7, 2023Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (Gmbh)Inventors: Vasilis Ntziachristos, Juan Aguirre Bueno
-
Patent number: 11578321Abstract: The present invention discloses a method for assessing the capacity of a substance to treat or prevent hepadnavirus infection. A reporter virus carrying genetic information for a first fragment of a recombinase and a reporter cell expressing a second fragment of the recombinase are used. When the reporter virus infects the reporter cell, the two fragments of the recombinase associate and excise a stop cassette that is flanked by two recombination sites and blocks the expression of a reporter gene. Accordingly, the present invention relates to a method of assessing the capacity of a substance to treat or prevent hepadnavirus infection, a hepadnavirus comprising a nucleic acid encoding a first fragment of a recombinase and a mammalian hepatocyte or hepatoma cell comprising a nucleic acid encoding a second fragment of a recombinase and a nucleic acid comprising a stop cassette flanked by two recombination sites fused to a reporter gene.Type: GrantFiled: August 15, 2019Date of Patent: February 14, 2023Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Technische Universität MünchenInventors: Wen-Min Chou, Ulrike Protzer-Knolle, Martin Mueck-Haeusl, Chunkyu Ko, Jochen Wettengel
-
Patent number: 11530273Abstract: The present invention relates to improved anti-CD73 antibodies which, in comparison to prior art anti-CD73 antibodies bind to a membrane-bound form of CD73 protein having cancer-promoting role and inhibit its enzymatic activity, while essentially not inhibiting a soluble form of CD73 protein involved in cardioprotection. The present invention further relates to methods of generation of such specific anti-CD73 antibodies and uses thereof including uses as medicaments and in methods for treatment, amelioration, prophylaxis and diagnostics of cancer.Type: GrantFiled: May 23, 2018Date of Patent: December 20, 2022Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Reinhard Zeidler, Bettina Von Neubeck, Regina Feederle, Stefanie Hauck
-
Publication number: 20220333120Abstract: The present invention relates to a method for preparing a bactericidal phage vector, (pharmaceutical) compositions comprising such phage vectors, also for use in treating diseases, particularly those caused by (antimicrobial resistance) bacterial cells.Type: ApplicationFiled: September 10, 2020Publication date: October 20, 2022Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Li Deng, Haiying Huang, Jinling Xue
-
Publication number: 20220236187Abstract: The present invention relates to systems, methods and fluorophores for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorophores.Type: ApplicationFiled: June 7, 2020Publication date: July 28, 2022Applicants: HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Oliver BRUNS, Jakob LINGG, Martin WARMER, Shyam S. RAMAKRISHNAN, Mara SACCOMANO, Ellen SLETTEN, Emily COSCO
-
Publication number: 20220236280Abstract: The present invention relates to systems, methods and fluorescent polypeptide for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorescent polypeptide.Type: ApplicationFiled: June 7, 2020Publication date: July 28, 2022Applicants: HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Oliver BRUNS, Jakob LINGG, Juan-Pablo FUENZALIDA-WERNER, Andre STIEL, Martin WARMER, Shyam S. RAMAKRISHNAN,, Emily COSCO, Ellen SLETTEN
-
Patent number: 11365237Abstract: The present invention relates to fusion proteins comprising (a) an extracellular domain containing a polypeptide derived from PD-1 or CD40L at its N-terminus; (b) a transmembrane domain; and (c) an intracellular domain containing a polypeptide derived from 4-1BB or CD28 at its C-terminus. Also, fusion proteins with CD28 at the N-terminus and CD40L at the C-terminus are envisaged. The present invention also relates to nucleic acid molecules encoding such fusion proteins, vectors containing such nucleic acid molecules, and host cells containing such vectors. The present invention further relates to methods for producing such host cells. Finally, the present invention relates to pharmaceutical compositions comprising such fusion proteins, nucleic acid molecules, vectors, and/or host cells, particularly for treating diseases or disorders associated with PD-1/PD-L2 or CD40 binding and/or PD-L1/PD-L2 or CD40 expression such as cancer and chronic viral infection.Type: GrantFiled: March 23, 2017Date of Patent: June 21, 2022Assignee: HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH)Inventors: Elfriede Noessner, Ramona Schlenker, Stephan Weisz
-
Patent number: 11185548Abstract: The present invention relates to compounds for use in treating a disease that is associated with (related to) CYP7B1 wherein the compound inhibits CYP7B1. The present invention further relates to a method of treating or preventing such a disease by administering an inhibitor of CYP7B1. The present invention also relates to a method of determining whether a compound is effective in treating or preventing a disease associated with the formation of inducible bronchus-associated lymphoid tissue (iBALT).Type: GrantFiled: December 21, 2017Date of Patent: November 30, 2021Assignee: HELMHOLTZ ZENTRUM MUNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Ali Oender Yildirim, Oliver Eickelberg
-
Patent number: 11161902Abstract: In general, the present invention relates to the field of (bio-)medicine and in particular to various metabolic diseases. Specifically, the invention provides means and methods for diagnosing, monitoring and predicting the risk for developing metabolic diseases. The invention uses exosomes as biomarkers for the aforementioned purposes. Moreover, an antibody of the present invention capable of specifically recognizing tissue-specific exosomes is also provided.Type: GrantFiled: May 9, 2017Date of Patent: November 2, 2021Assignee: Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (GmbH)Inventors: Kerstin Stemmer, Matthias Tschöp, Michaela Bauer, Reinhard Zeidler, Regina Feederle
-
Patent number: 11155589Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.Type: GrantFiled: December 22, 2016Date of Patent: October 26, 2021Assignees: Medigene Immunotherapies GmbH, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Slavoljub Milosevic, Christian Ellinger, Carina Wehner, Dolores Schendel
-
Patent number: RE48992Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.Type: GrantFiled: October 31, 2019Date of Patent: March 29, 2022Assignee: Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn